Page 67 - CIBEREHD-2015-cast

Publicaciones científicas más relevantes
Grupos de Investigación
aFdhal n., zeuzeM s., KWo P., chojKieR M., Gitlin n., Puo- ti M. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine. 2014;370(20):1889-1898.
Manns M., MaRcellin P., PooRdad F., de aRaujo e.s.a., buti M., hoRsMans y. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infec- tion (QUEST-2): A randomised, double-blind, placebo-con- trolled phase 3 trial. The Lancet. 2014;384(9941):414-426.
RiveiRo-baRciela M., buti M., hoMs M., caMPos-vaRela i., cantaRell c., cResPo M. et al. Cirrhosis, liver transplan- tation and HIV infection are risk factors associated with hepatitis E virus infection. PLoS ONE. 2014;9(7).
hoMs M., GieRsch K., blasi M., lutGehetMann M., buti M., esteban R. et al. Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification. Journal of Clinical Microbiology. 2014;52(9):3334-3338.
hoMs M., caballeRo a., GReGoRi j., tabeRneRo d., queR j., nieto l. et al. Clinical application of estimating hepatitis b virus quasispecies complexity by massive sequencing: Correlation between natural evolution and on-treatment evolution. PLoS ONE. 2014;9(11).
Institución: Fundación Hospital Universitario Vall d´Hebron - Institut de Recerca (VHIR) Contacto: Hospital Vall d’Hebron. Passeig Vall d’Hebron, 119-129. 08035 Barcelona
CIBEREHD I Memoria anual 2015 I 67